ClinicalTrials.gg
CompletedNCT05142774Updated Aug 13, 2025Results posted

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

A Phase 3 interventional study of Tapinarof cream, 1% in Atopic Dermatitis, sponsored by Organon and Co. Completed at 112 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
728
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
Largest of 12
728 · median 168
Started
2021
with 3 others
Phase 3
5 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
5 of 12
Organon and Co

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 8th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.

Read the detailed description

At the completion of the Week 8 visit of study DMVT-505-3101 (NCT05014568) or study DMVT-505-3102 (NCT05032859) or the Day 28 visit of study DMVT-505-2104 (NCT05186805) (Day 1 [Baseline] in this study), all eligible subjects will be offered enrollment in this open-label long-term extension (OL-LTE) study. Approximately 125 additional pediatric subjects ages 2 to \< 18 years who are not eligible for participation in the Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) will be enrolled directly into this OL-LTE study. Study visits during the treatment period for all subjects will occur every 4 weeks (± 3 days). The total duration of study participation will be approximately 48 weeks for rollover subjects (Baseline to Final Visit) with a 1-week Safety Follow-up Period and approximately 52 weeks for direct-enrolling subjects (Screening to Final Visit) with a 1-week Safety Follow-up Period.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • pediatric
  • tapinarof
  • phase 3
  • topical
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Roll-over Subjects Only:

  • Met the criteria as a Study Completer in one of three studies (DMVT-505-3101 study, DMVT-505-3102 study, or DMVT-505-2104 study).
  • Must not be pregnant at Baseline

For Direct-Enrolling Subjects Only:

  • Male and female subjects ages 2 years to \< 18 years at the time of consent with clinical diagnosis of AD
  • Subjects with a vIGA-AD™ score of ≥ 3 and AD covering ≥ 40% of the BSA at Screening and Baseline (pre-randomization), or subjects with a vIGA-AD™ score of 2 at Screening and Baseline (pre-randomization) regardless of BSA. Subjects must have screened for the DMVT-505-3101 or DMVT-505-3102 study and failed to meet BSA and/or vIGA-AD™ eligibility criteria.
  • AD present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old
  • Must not be pregnant at Screening or Baseline

For All Subjects:

  • Female subjects of who are engaging in sexual activity that could lead to pregnancy should use acceptable methods
  • Subject, subject's parent, or legal representative must be capable of giving written /assent

Exclusion criteria

Exclusion Criteria:

For Rollover Subjects Only:

  1. Subjects who were not receiving study drug at the time of the last visit in the pivotal study (DMVT-505-3101, DMVT-505-3102, or DMVT-505-2104)
  2. Used a prohibited concomitant product or procedure to treat AD during the pivotal study.
  3. Had an SAE that was related to treatment or experienced an AE that led to permanent discontinuation of treatment in the pivotal study.
  4. Pregnant females

For Direct-Enrolling Subjects:

  • at screening
  • Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit
  • Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥2.0x the (ULN).
  • Screening total > 1.5x ULN
  • Current or chronic history of liver disease
  • Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects who would not be considered suitable for topical therapy
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give .
  • Pregnant or lactating females
  • History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
728 participants (actual)

Study arms

  • Experimental
    tapinarof cream

    Subjects entering with vIGA-AD (Validated Investigator Global Assessment of Atopic Dermatitis) ≥1 receive treatment with study drug until they achieve vIGA-AD=0, at which time treatment is discontinued and subjects are monitored for durability of response (remittive response). If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved. Subjects entering with a vIGA-AD=0 discontinue treatment and are monitored for duration of remittive response. If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved. This treatment and re-treatment pattern of use continue until the end of the study.

    Drug: Tapinarof cream, 1%

Interventions

  • Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events

    For rollover subjects, all AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug will be considered a TEAE.

    Time frame: Baseline to Week 49

  2. Frequency of Adverse Events and Serious Adverse Events

    All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE.

    Time frame: Baseline to Week 49

  3. Change From Baseline in Clinical Laboratory Values (g/L)

    The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  4. Change From Baseline in Clinical Laboratory Values (U/L)

    The mean chemistry parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  5. Change From Baseline in Clinical Laboratory Values (mmol/L)

    The mean chemistry parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  6. Change From Baseline in Clinical Laboratory Values (Umol/L)

    The mean chemistry parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  7. Change From Baseline in Clinical Laboratory Values (10^9 Cells/L)

    The mean hematology parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  8. Change From Baseline in Clinical Laboratory Values (%)

    The mean hematology parameters were assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  9. Change From Baseline in Clinical Laboratory Values (L/L)

    The hematology parameter, Hematocrit, was assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  10. Change From Baseline in Clinical Laboratory Values (pg)

    The hematology parameter, Ery. Mean Corpuscular Hemoglobin was assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  11. Change From Baseline in Clinical Laboratory Values (fl)

    The hematology parameter, Ery. Mean Corpuscular Volume, was assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  12. Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)

    The hematology parameter, Erythrocytes, was assessed for changes and trends over the course of the study.

    Time frame: Baseline to Week 48

  13. Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.

    Time frame: Baseline to Week 48

  14. Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.

    Time frame: Baseline to Week 48

  15. Absolute Change From Baseline in %BSA Affected

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 48

  16. Percent Change From Baseline in %BSA Affected

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 48

  17. Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Week 48

  18. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Week 48

  19. Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

    The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Week 48

  20. Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

    The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Week 48

  21. Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

    The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

    Time frame: Baseline to Week 48

  22. Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline

    The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.

    Time frame: Baseline to Week 48

  23. Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline

    The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.

    Time frame: Baseline to Week 48

  24. Change From Baseline in Vital Signs - Pulse

    The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

    Time frame: Baseline to Week 48

  25. Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)

    The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

    Time frame: Baseline to Week 48

  26. Change From Baseline in Vital Signs - Temperature

    The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

    Time frame: Baseline to Week 48

07

Results

Posted Aug 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneTapinarof Cream
Started728
Completed497
Not completed231

Outcome measures

PrimaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events

For rollover subjects, all AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug will be considered a TEAE.

Time frame:
Baseline to Week 49
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events
ParticipantsTapinarof Cream
Any treatment-emergent AE451
Serious treatment-emergent AE34
PrimaryFrequency of Adverse Events and Serious Adverse Events

All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE.

Time frame:
Baseline to Week 49
Reported as:
Number · Events
Frequency of Adverse Events and Serious Adverse Events
EventsTapinarof Cream
Treatment-emergent AE1226
Serious treatment-emergent AE45
PrimaryChange From Baseline in Clinical Laboratory Values (g/L)

The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · g/L
Change From Baseline in Clinical Laboratory Values (g/L)
g/LTapinarof Cream
Albumin (g/L)-0.5 ± 2.43
Protein (g/L)0.0 ± 3.95
Hemoglobin (g/L)1.7 ± 8.45
Ery. Mean Corpuscular HGB Concentration (g/L)0.0 ± 7.61
PrimaryChange From Baseline in Clinical Laboratory Values (U/L)

The mean chemistry parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · U/L
Change From Baseline in Clinical Laboratory Values (U/L)
U/LTapinarof Cream
Alkaline Phosphatase (U/L)-14.9 ± 69.45
Alanine Aminotransferase (U/L)-1.5 ± 11.96
Aspartate Aminotransferase (U/L)-2.6 ± 16.13
PrimaryChange From Baseline in Clinical Laboratory Values (mmol/L)

The mean chemistry parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · mmol/L
Change From Baseline in Clinical Laboratory Values (mmol/L)
mmol/LTapinarof Cream
Bicarbonate (mmol/L)-0.2 ± 2.31
Blood Urea Nitrogen (mmol/L)0.04 ± 1.428
Calcium (mmol/L)-0.019 ± 0.0926
Chloride (mmol/L)-0.3 ± 2.43
Glucose (mmol/L)0.13 ± 1.462
Potassium (mmol/L)-0.03 ± 0.493
Sodium (mmol/L)-0.1 ± 2.14
PrimaryChange From Baseline in Clinical Laboratory Values (Umol/L)

The mean chemistry parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · umol/L
Change From Baseline in Clinical Laboratory Values (Umol/L)
umol/LTapinarof Cream
Bilirubin (umol/L)0.40 ± 3.434
Enzymatic Creatinine (umol/L)2.1 ± 7.92
Creatinine (Jaffe) (umol/L)2.7 ± 12.06
Urate (umol/L)0.9 ± 52.32
PrimaryChange From Baseline in Clinical Laboratory Values (10^9 Cells/L)

The mean hematology parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Clinical Laboratory Values (10^9 Cells/L)
10^9 cells/LTapinarof Cream
Basophils (10^9/L)0.01 ± 0.051
Eosinophils (10^9/L)-.03 ± 0.308
Lymphocytes (10^9/L)-0.02 ± 0.909
Monocytes (10^9/L)0.00 ± 0.192
Neutrophils (10^9/L)0.22 ± 2.079
Platelets (10^9/L)-4.0 ± 59.57
Leukocytes (10^9/L)0.18 ± 2.474
PrimaryChange From Baseline in Clinical Laboratory Values (%)

The mean hematology parameters were assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · % of cells
Change From Baseline in Clinical Laboratory Values (%)
% of cellsTapinarof Cream
Basophils/Total Cells (%)0.03 ± 0.272
Eosinophils/Total Cells (%)-0.39 ± 3.427
Lymphocytes/Total Cells (%)-0.73 ± 10.440
Monocytes/Total Cells (%)-0.09 ± 2.592
Neutrophils/Total Cells (%)1.18 ± 11.436
Reticulocytes/Erythrocytes (%)-0.06 ± 0.402
PrimaryChange From Baseline in Clinical Laboratory Values (L/L)

The hematology parameter, Hematocrit, was assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · L/L
Change From Baseline in Clinical Laboratory Values (L/L)
L/LTapinarof Cream
Change From Baseline in Clinical Laboratory Values (L/L)0.005 ± 0.0263
PrimaryChange From Baseline in Clinical Laboratory Values (pg)

The hematology parameter, Ery. Mean Corpuscular Hemoglobin was assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · pg
Change From Baseline in Clinical Laboratory Values (pg)
pgTapinarof Cream
Change From Baseline in Clinical Laboratory Values (pg)0.13 ± 0.823
PrimaryChange From Baseline in Clinical Laboratory Values (fl)

The hematology parameter, Ery. Mean Corpuscular Volume, was assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · fl
Change From Baseline in Clinical Laboratory Values (fl)
flTapinarof Cream
Change From Baseline in Clinical Laboratory Values (fl)0.37 ± 2.364
PrimaryChange From Baseline in Clinical Laboratory Values (10^12 Cells/L)

The hematology parameter, Erythrocytes, was assessed for changes and trends over the course of the study.

Time frame:
Baseline to Week 48
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)
10^12 cells/LTapinarof Cream
Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)0.038 ± 0.2905
PrimaryComplete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )
ParticipantsTapinarof Cream
Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )320
PrimaryResponse During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)
ParticipantsTapinarof Cream
Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)347
PrimaryAbsolute Change From Baseline in %BSA Affected

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 48
Reported as:
Mean · percentage of BSA
Absolute Change From Baseline in %BSA Affected
percentage of BSATapinarof Cream
Absolute Change From Baseline in %BSA Affected-7.14 ± 12.881
PrimaryPercent Change From Baseline in %BSA Affected

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 48
Reported as:
Mean · percent change from baseline in % total
Percent Change From Baseline in %BSA Affected
percent change from baseline in % totalTapinarof Cream
Percent Change From Baseline in %BSA Affected-37.45 ± 189.905
PrimaryMean Change From Baseline in Eczema Area and Severity Index (EASI) Score

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score
Units on a scaleTapinarof Cream
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score-4.19 ± 7.248
PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score
Units on a scaleTapinarof Cream
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score-33.70 ± 139.557
PrimaryPercent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
ParticipantsTapinarof Cream
Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.325
PrimaryPercent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
ParticipantsTapinarof Cream
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.256
PrimaryPercent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.

The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
ParticipantsTapinarof Cream
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.178
PrimaryMean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline

The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.

Time frame:
Baseline to Week 48
Reported as:
Mean · Units on a scale
Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline
Units on a scaleTapinarof Cream
Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline-1.618 ± 2.7756
PrimaryNumber of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline

The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline
ParticipantsTapinarof Cream
Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline94
PrimaryChange From Baseline in Vital Signs - Pulse

The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

Time frame:
Baseline to Week 48
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Vital Signs - Pulse
beats per minute (bpm)Tapinarof Cream
Change From Baseline in Vital Signs - Pulse-0.9 ± 12.61
PrimaryChange From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)

The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

Time frame:
Baseline to Week 48
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)
mmHgTapinarof Cream
Systolic Blood Pressure (mmHg)1.0 ± 10.72
Diastolic Blood Pressure (mmHg)0.7 ± 9.78
PrimaryChange From Baseline in Vital Signs - Temperature

The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.

Time frame:
Baseline to Week 48
Reported as:
Mean · degrees C
Change From Baseline in Vital Signs - Temperature
degrees CTapinarof Cream
Change From Baseline in Vital Signs - Temperature0.02 ± 0.437

Adverse events

Collected over For rollover subjects, all AEs reported in this extension study, through study completion, up to 48 weeks, were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug and through study completion, up to 48 weeks, will be considered a TEAE.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Continuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score0/728 (0%)34/728 (4.7%)451/728 (62%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventContinuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score
AsthmaRespiratory, thoracic and mediastinal disorders19/728
PneumoniaInfections and infestations5/728
Status asthmaticusRespiratory, thoracic and mediastinal disorders3/728
Anaphylactic reactionImmune system disorders2/728
HypothyroidismEndocrine disorders1/728
AppendicitisInfections and infestations1/728
Pneumonia respiratory syncytial viralInfections and infestations1/728
Postoperative abscessInfections and infestations1/728
Respiratory syncytial virus infectionInfections and infestations1/728
Humerus fractureInjury, poisoning and procedural complications1/728
Most frequent other events
Showing 10 of 16
Most frequent other events
EventContinuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score
FolliculitisInfections and infestations88/728
NasopharyngitisInfections and infestations50/728
Upper respiratory tract infectionInfections and infestations50/728
AsthmaRespiratory, thoracic and mediastinal disorders44/728
COVID-19Infections and infestations42/728
InfluenzaInfections and infestations27/728
HeadacheNervous system disorders25/728
CoughRespiratory, thoracic and mediastinal disorders24/728
ImpetigoInfections and infestations22/728
Pharyngitis streptococcalInfections and infestations21/728

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Tapinarof Cream
Mean15.0 ± 15.32
Age, Customized
Age, Customized(Participants)Tapinarof Cream
2-6 years194
7-11 years197
12-17 years213
≥18 years124
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof Cream
Female389
Male339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof Cream
Hispanic or Latino163
Not Hispanic or Latino562
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof Cream
American Indian or Alaska Native4
Asian81
Native Hawaiian or Other Pacific Islander1
Black or African American219
White383
More than one race27
Unknown or Not Reported13
Region of Enrollment
Region of Enrollment(Count of participants)Tapinarof Cream
Canada112
United States616
Validated Investigator Global Assessment for Atopic Dermatitis
Validated Investigator Global Assessment for Atopic Dermatitis(Participants)Tapinarof Cream
0 - clear58
1 - almost clear189
2 - mild268
3 - moderate182
4 - severe31
Percent Body Surface Area (BSA)
Percent Body Surface Area (BSA)(Affected Body Surface Area percentage)Tapinarof Cream
Mean10.62 ± 14.259

1 further baseline measures are reported on the registry.

08

Study locations

112 sites
  • Dermavant Investigative Site
    Birmingham, Alabama 35244, United States
  • Dermavant Investigative Site
    Phoenix, Arizona 85032, United States
  • Dermavant Investigative Site
    Scottsdale, Arizona 85255, United States
  • Dermavant Investigative Site
    Scottsdale, Arizona 85260, United States
  • Dermavant Investigative Site
    Bryant, Arkansas 72022, United States
  • Dermavant Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Dermavant Investigative Site
    Cerritos, California 90702, United States
  • Dermavant Investigative Site
    Fountain Valley, California 92708, United States
  • Dermavant Investigative Site
    Fremont, California 94538, United States
  • Dermavant Investigative Site
    Huntington Beach, California 92647, United States
  • Dermavant Investigative Site
    Inglewood, California 90301, United States
  • Dermavant Investigative Site
    Lancaster, California 93534, United States
  • Dermavant Investigative Site
    Long Beach, California 90806, United States
  • Dermavant Investigative Site
    Los Angeles, California 90017, United States
  • Dermavant Investigative Site
    Los Angeles, California 90033, United States
  • Dermavant Investigative Site
    Los Angeles, California 90045, United States
  • Dermavant Investigative Site
    Mission Viejo, California 92691, United States
  • Dermavant Investigative Site
    Sacramento, California 95815, United States
  • Dermavant Investigative Site
    San Diego, California 92123, United States
  • Dermavant Investigative Site
    San Francisco, California 94115, United States
  • Dermavant Investigative Site
    Santa Ana, California 92701, United States
  • Dermavant Investigative Site
    Santa Monica, California 90404, United States
  • Dermavant Investigative Site
    Thousand Oaks, California 91320, United States
  • Dermavant Investigative Site
    Thornton, Colorado 80112, United States
  • Dermavant Investigative Site
    Washington D.C., District of Columbia 20037, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33428, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33486, United States
  • Dermavant Investigative Site
    Brandon, Florida 33511, United States
  • Dermavant Investigative Site
    Coral Gables, Florida 33146, United States
  • Dermavant Investigative Site
    Delray Beach, Florida 33484, United States
  • Dermavant Investigative Site
    Hialeah, Florida 33016, United States
  • Dermavant Investigative Site
    Jacksonville, Florida 32256, United States
  • Dermavant Investigative Site
    Margate, Florida 33063, United States
  • Dermavant Investigative Site
    Miami, Florida 33165, United States
  • Dermavant Investigative Site
    Miami, Florida 33173, United States
  • Dermavant Investigative Site
    Miami Lakes, Florida 33014, United States
  • Dermavant Investigative Site
    Orlando, Florida 32801, United States
  • Dermavant Investigative Site
    Pinellas Park, Florida 33781, United States
  • Dermavant Investigative Site
    Sweetwater, Florida 33172, United States
  • Dermavant Investigative Site
    Tampa, Florida 33607, United States
  • Dermavant Investigative Site
    Marietta, Georgia 30060, United States
  • Dermavant Investigative Site
    Sandy Springs, Georgia 30328, United States
  • Dermavant Investigative Site
    Savannah, Georgia 31406, United States
  • Dermavant Investigative Site
    Snellville, Georgia 30078, United States
  • Dermavant Investigative Site
    Chicago, Illinois 60611, United States
  • Dermavant Investigative Site
    Evansville, Indiana 47715, United States
  • Dermavant Investigative Site
    Plainfield, Indiana 46168, United States
  • Dermavant Investigative Site
    Overland Park, Kansas 66210, United States
  • Dermavant Investigative Site
    Lexington, Kentucky 40517, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40217, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40241, United States
  • Dermavant Investigative Site
    Owensboro, Kentucky 42301, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70808, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Dermavant Investigative Site
    Covington, Louisiana 70433, United States
  • Dermavant Investigative Site
    Monroe, Louisiana 71201, United States
  • Dermavant Investigative Site
    New Orleans, Louisiana 70115, United States
  • Dermavant Investigative Site
    Largo, Maryland 20774, United States
  • Dermavant Investigative Site
    Rockville, Maryland 20850, United States
  • Dermavant Investigative Site
    Bay City, Michigan 48706, United States
  • Dermavant Investigative Site
    Clarkston, Michigan 48346, United States
  • Dermavant Investigative Site
    Warren, Michigan 48088, United States
  • Dermavant Investigative Site
    Ypsilanti, Michigan 48197, United States
  • Dermavant Investigative Site
    New Brighton, Minnesota 55112, United States
  • Dermavant Investigative Site
    Missoula, Montana 59808, United States
  • Dermavant Investigative Site
    Omaha, Nebraska 68144, United States
  • Dermavant Investigative Site
    East Windsor, New Jersey 08520, United States
  • Dermavant Investigative Site
    Garden City, New York 11530, United States
  • Dermavant Investigative Site
    New York, New York 10075, United States
  • Dermavant Investigative Site
    Charlotte, North Carolina 28277, United States
  • Dermavant Investigative Site
    Bexley, Ohio 43209, United States
  • Dermavant Investigative Site
    Cleveland, Ohio 44106, United States
  • Dermavant Investigative Site
    Dayton, Ohio 45414, United States
  • Dermavant Investigative Site
    Mason, Ohio 45040, United States
  • Dermavant Investigative Site
    Mayfield Heights, Ohio 44124, United States
  • Dermavant Investigative Site
    Norman, Oklahoma 73071, United States
  • Dermavant Investigative Site
    Oklahoma City, Oklahoma 73120, United States
  • Dermavant Investigative Site
    Tulsa, Oklahoma 74114, United States
  • Dermavant Investigative Site
    Medford, Oregon 97504, United States
  • Dermavant Investigative Site
    Portland, Oregon 97210, United States
  • Dermavant Investigative Site
    Portland, Oregon 97223, United States
  • Dermavant Investigative Site
    Portland, Oregon 97239, United States
  • Dermavant Investigative Site
    Anderson, South Carolina 29621, United States
  • Dermavant lnvestigative Site
    Greenville, South Carolina 29615, United States
  • Dermavant Investigative Site
    Mt. Pleasant, South Carolina 29445, United States
  • Dermavant Investigative Site
    North Charleston, South Carolina 29420, United States
  • Dermavant Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Dermavant Investigative Site
    Knoxville, Tennessee 37909, United States
  • Dermavant Investigative Site
    Memphis, Tennessee 38119, United States
  • Dermavant Investigative Site
    Bellaire, Texas 77401, United States
  • Dermavant Investigative Site
    Cypress, Texas 77433, United States
  • Dermavant Investigative Site
    Dallas, Texas 75230, United States
  • Dermavant Investigative Site
    Dripping Springs, Texas 78620, United States
  • Dermavant Investigative Site
    Grapevine, Texas 76051, United States
  • Dermavant Investigative Site
    Houston, Texas 77004, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78218, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78229, United States
  • Dermavant Investigative Site
    Sugar Land, Texas 77479, United States
  • Dermavant Investigative Site
    Webster, Texas 77598, United States

Showing the first 100 of 112 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gold LS, Bruno MJ, Lewitt GM, Hebert AA. Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. J Dermatolog Treat. 2025 Dec;36(1):2517388. doi: 10.1080/09546634.2025.2517388. Epub 2025 Jul 2. PubMed 40600584 ↗
  • Bissonnette R, Stein Gold L, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025 Sep;93(3):707-714. doi: 10.1016/j.jaad.2025.05.1391. Epub 2025 May 16. PubMed 40383273 ↗
  • Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024 Sep;91(3):457-465. doi: 10.1016/j.jaad.2024.05.023. Epub 2024 May 20. PubMed 38777187 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2024, 28 months.

Results were first posted in Aug 2025, 1 year 5 months after primary completion. A results delay was requested in Apr 2024.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Dec 3, 2021
StartActual
Oct 28, 2021
Primary completionActual
Feb 29, 2024
CompletionActual
Mar 7, 2024
Results delay requested
Apr 5, 2024
Results first posted
Aug 13, 2025
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05142774
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Oct 28, 2021
Primary completion
Feb 29, 2024
Completion
Mar 7, 2024
Results posted
Aug 13, 2025
Last update
Aug 13, 2025

Study contacts

Diana Villalobos
study director · Dermavant Sciences, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion